Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years

Ascione, Antonio; Fontanella, Luca; Imparato, Michele; Rinaldi, Luca; Luca, Massimo De

doi:10.1111/liv.13371

Cited by 43 publications

(36 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, it is possible that the burden of mortality in ESLD shifted from in‐hospital to the early post‐discharge period . Several studies from Europe and Australia have confirmed a marked reduction of in‐hospital mortality among patients with cirrhosis, but without assessment of mortality rates in the outpatient setting following the discharge from the hospital …”

Section: Discussionmentioning

confidence: 99%

“…25 Several studies from Europe and Australia have confirmed a marked reduction of in-hospital mortality among patients with cirrhosis, but without assessment of mortality rates in the outpatient setting following the discharge from the hospital. [26][27][28] The strengths of our study are the utilization of a nationwide database. Our study represents outcomes of a large population of hospitalized patients with ESLD over a 10-year period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014

Kim

Cholankeril

et al. 2019

Liver International

View full text Add to dashboard Cite

Background & Aims Current estimates of the population‐based disease burden of liver failure or end‐stage liver disease (ESLD) are lacking. We investigated recent trends in hospitalizations and in‐hospital mortality among patients with ESLD in the United States (US). Methods A retrospective analysis was performed utilizing the National Inpatient Sample from 2005 to 2014. We defined ESLD as either decompensated cirrhosis or hepatocellular carcinoma (HCC), criteria obtained from the International Classification of Diseases, Ninth Revision. Nationwide rates of hospitalization and in‐hospital mortality were analysed from 2005 to 2014. Results Hospitalization rates for decompensated cirrhosis during this period increased from 105.3/100 000 persons to 159.9/100 000 persons. In terms of HCC, hospitalization rates increased from 13.6/100 000 to 22.1/100 000. In patients with non‐alcoholic fatty liver disease (NAFLD)‐related decompensated cirrhosis, the hospitalization rate increased from 13.4/100 000 to 32.1/100 000 with an annual incremental increase of 10.6%, a magnitude twofold higher than other aetiologies. The proportion of NAFLD among hospitalizations with ESLD steadily increased from 12.7% to 20.1% for decompensated cirrhosis while the proportion of chronic hepatitis C (HCV) and alcoholic liver disease (ALD) declined (from 29.3% to 27.6% for HCV; from 39.0% to 37.4% for ALD). Although the overall in‐hospital mortality rates for ESLD declined during the study, mortality rates for NAFLD‐related decompensated cirrhosis showed no significant change. Conclusions Among aetiologies of chronic liver disease, NAFLD demonstrated the fastest growing rate of hospitalizations in non‐HCC patients with ESLD in the US. Our study highlights the need for a focus on NAFLD‐related hospitalizations and its impact on resource utilization.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014

Kim

Cholankeril

et al. 2019

Liver International

View full text Add to dashboard Cite

show abstract

“…In Italy, liver cirrhosis (LC) and hepatocellular carcinoma (HCC) are the two main causes of death due to liver diseases. These two serious conditions caused, according to the last available data, 8071 deaths from LC and 10,116 from HCC [1]. Several Italian studies over the years have shown that, at least in 65% of cases, these two diseases are linked to HCV chronic infection [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Ascione¹,

Luca²,

Melazzini³

et al. 2018

Infection

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 Hepatocellular carcinoma (HCC) is the predominant primary liver cancer in many countries, and HCC-related mortality continues to increase. [2][3][4] The computed tomography (CT) and magnetic resonance imaging (MRI) characteristics of HCC are well described, and the diagnostic algorithm for HCC [Liver reporting and data system (LI-RADS)], which is based on CT, MRI with extracellular contrast material, or MRI with hepatobiliary contrast material (namely, gadoxetate disodium, also known by the trade name Primovist or Eovist), has been established. 5,6 Gadoxetate disodium is a liver-specific contrast material that allows both dynamic study and hepatocyte imaging at the hepatobiliary phase (HBP).…”

Section: Introductionmentioning

confidence: 99%

Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study

et al. 2021

View full text Add to dashboard Cite

Purpose:To determine the optimal combination of gadoxetate disodium-enhanced magnetic resonance imaging (MRI) findings for the diagnosis of hepatocellular carcinoma (HCC) and to compare its diagnostic ability to that of dynamic computed tomography (CT) in patients with chronic liver disease. Methods:This multi-institutional study consisted of two parts: Study 1, a retrospective study to determine the optimal combination of gadoxetate disodium-enhanced MRI findings (decision tree and logistic model) to distinguish HCC (n = 199) from benign (n = 81) or other malignant lesions (n = 95) (375 nodules in 269 patients) and Study 2, a prospective study to compare the diagnostic ability of gadoxetate disodiumenhanced MRI to distinguish HCC (n = 73) from benign (n = 15) or other malignant lesions (n = 12) with that of dynamic CT (100 nodules in 83 patients). Two radiologists independently evaluated the imaging findings (Study 1 and 2) and made a practical diagnosis (Study 2). Results:In Study 1, rim or whole enhancement on arterial phase images, signal intensities on T 2 -weighted/ diffusion-weighted/portal venous/transitional/hepatobiliary phase images, and signal drop on opposedphase images were independently useful for differential diagnosis. In Study 2, the accuracy, sensitivity, negative predictive value, and negative likelihood ratio of the CT decision tree (reader 2) were higher than those of MRI Model 2 (P = 0.015-0.033). There were no other significant differences in diagnostic ability (P = 0.059-1.000) and radiologist-made practical diagnosis (P = 0.059-1.000) between gadoxetate disodiumenhanced MRI and CT. Conclusion:We identified the optimal combination of gadoxetate disodium-enhanced MRI findings for HCC diagnosis. However, its diagnostic ability was not superior to that of dynamic CT.

show abstract

Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years

Abstract: The LC mortality rate is decreasing in Europe, yet there is a significant increase in HCC mortality. This phenomenon requires greater attention so we can understand the risk factors and implement preventive measures.

Cited by 43 publications

References 48 publications

Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014

Trends in hospitalizations for chronic liver disease‐related liver failure in the United States, 2005‐2014

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study

Contact Info

Product

Resources

About